Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMD

NCT07694986 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Leptomeningeal Disease

Interventions

BIOLOGICAL: cDC1 Vaccine
DRUG: Trastuzumab
DRUG: Nivolumab

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]